Business Description
Middle East Pharmaceutical Industries Co
ISIN : SA160G51UO10
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.19 | |||||
Equity-to-Asset | 0.66 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | 2.23 | |||||
Interest Coverage | 19.24 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 43.69 | |||||
9-Day RSI | 39.84 | |||||
14-Day RSI | 38.63 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.23 | |||||
Quick Ratio | 1.43 | |||||
Cash Ratio | 0.1 | |||||
Days Inventory | 597.21 | |||||
Days Sales Outstanding | 343.65 | |||||
Days Payable | 213.15 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.63 | |||||
Dividend Payout Ratio | 0.59 | |||||
Forward Dividend Yield % | 0.63 | |||||
5-Year Yield-on-Cost % | 0.63 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 60.99 | |||||
Operating Margin % | 17.27 | |||||
Net Margin % | 14.09 | |||||
FCF Margin % | -16.19 | |||||
ROE % | 7.74 | |||||
ROA % | 5.35 | |||||
ROIC % | 6.37 | |||||
ROC (Joel Greenblatt) % | 9.46 | |||||
ROCE % | 8.64 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 92.66 | |||||
PE Ratio without NRI | 92.66 | |||||
PS Ratio | 13.02 | |||||
PB Ratio | 7.27 | |||||
Price-to-Tangible-Book | 8.58 | |||||
EV-to-EBIT | 79.59 | |||||
EV-to-EBITDA | 73.8 | |||||
EV-to-Revenue | 13.35 | |||||
EV-to-FCF | -82.04 | |||||
Price-to-Graham-Number | 5.94 | |||||
Price-to-Net-Current-Asset-Value | 15.21 | |||||
Earnings Yield (Greenblatt) % | 1.25 | |||||
FCF Yield % | -1.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Middle East Pharmaceutical Industries Co Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil ï·¼) | 182.193 | ||
EPS (TTM) (ï·¼) | 1.28 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 38.63 | ||
14-Day ATR (ï·¼) | 2.077544 | ||
20-Day SMA (ï·¼) | 120.21 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (ï·¼) | 107 - 144.6 | ||
Shares Outstanding (Mil) | 20 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Middle East Pharmaceutical Industries Co Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Middle East Pharmaceutical Industries Co Stock Events
Event | Date | Price(ï·¼) | ||
---|---|---|---|---|
No Event Data |
Middle East Pharmaceutical Industries Co Frequently Asked Questions
What is Middle East Pharmaceutical Industries Co(SAU:4016)'s stock price today?
When is next earnings date of Middle East Pharmaceutical Industries Co(SAU:4016)?
Does Middle East Pharmaceutical Industries Co(SAU:4016) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |